These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3987929)

  • 1. Pergolide mesylate inhibits exercise-induced prolactin release in man.
    De Meirleir K; Baeyens L; L'Hermite M; L'Hermite-Balériaux M; Olbrecht J; Holmann W
    Fertil Steril; 1985 Apr; 43(4):628-31. PubMed ID: 3987929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pergolide mesylate: its effects on circulating anterior pituitary hormones in man.
    Perryman RL; Rogol AD; Kaiser DL; MacLeod RM; Thorner MO
    J Clin Endocrinol Metab; 1981 Oct; 53(4):772-8. PubMed ID: 6793609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent 48 hours inhibition of prolactin secretion by pergolide in hyperprolactinaemic women.
    L'Hermite M; Debusschere P
    Acta Endocrinol (Copenh); 1982 Dec; 101(4):481-3. PubMed ID: 7158225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pergolide on diethylstilbestrol-induced rat pituitary hyperplasia.
    Lloyd RV; Schmidt K; Nath V
    Am J Pathol; 1985 Dec; 121(3):486-95. PubMed ID: 4073221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pergolide, a potent long-acting dopamine-receptor agonist.
    Lemberger L; Crabtree R; Callaghan JT
    Clin Pharmacol Ther; 1980 May; 27(5):642-51. PubMed ID: 7189453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability and selectivity of anterior pituitary response to dopamine agonists throughout the normal menstrual cycle.
    Kletzky OA; Shangold GA
    Am J Obstet Gynecol; 1986 Feb; 154(2):362-7. PubMed ID: 3080890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term monolayer culture of human anterior pituitary cells: functional validation of a method.
    Rodgers-Neame NT; Bradley EL; Blackwell RE
    Fertil Steril; 1984 Jan; 41(1):75-80. PubMed ID: 6420206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson's disease.
    Kleinberg DL; Lieberman A; Todd J; Greising J; Neophytides A; Kupersmith M
    J Clin Endocrinol Metab; 1980 Jul; 51(1):152-4. PubMed ID: 6769937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of the dopamine agonist, lergotrile mesylate, on prolactin secretion in women.
    Leebaw W; Lee L; Woolf P
    Acta Endocrinol (Copenh); 1978 Jan; 87(1):12-8. PubMed ID: 579527
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative study of central dopaminergic properties of RU 29717 (N-propyl-9-oxaergoline) and pergolide.
    Boissier JR; Euvrard C; Oberlander C; Laurent J; Dumont C; Labrie F
    Eur J Pharmacol; 1983 Feb; 87(2-3):183-9. PubMed ID: 6857756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulatory effects of quinpirole hydrochloride, D2-dopamine receptor agonist, at low concentrations on prolactin release in female rats in vitro.
    Tagawa R; Takahara J; Sato M; Niimi M; Murao K; Ishida T
    Life Sci; 1992; 51(10):727-32. PubMed ID: 1355255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary.
    Pisarek H; Stepien H; Pawlikowski M
    Endocr Regul; 1992 Mar; 26(1):17-22. PubMed ID: 1421203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in size of prolactin-secreting tumours in men treated with pergolide.
    Kendall-Taylor P; Hall K; Johnston DG; Prescott RW
    Br Med J (Clin Res Ed); 1982 Aug; 285(6340):465-7. PubMed ID: 6809126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of epinephrine in rat hypothalamus by a dopamine agonist, pergolide.
    Fuller RW; Perry KW; Hemrick-Luecke SK
    Neurochem Res; 1982 Apr; 7(4):399-405. PubMed ID: 6125905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
    Franks S; Horrocks PM; Lynch SS; Butt WR; London DR
    Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1177-9. PubMed ID: 6404378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of [3H]SCH 23390 specific binding sites in anterior pituitary: dissociation from effects on prolactin secretion.
    Rovescalli AC; Brunello N; Monopoli A; Ongini E; Racagni G
    Eur J Pharmacol; 1987 Mar; 135(2):129-36. PubMed ID: 3556197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of prolactin release and mRNA accumulation by two novel dopamine agonist agents.
    Davis JR; Vidal ME; Wilson EM; Sheppard MC
    Acta Endocrinol (Copenh); 1989 May; 120(5):672-6. PubMed ID: 2567101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist.
    Lemberger L; Crabtree RE
    Science; 1979 Sep; 205(4411):1151-3. PubMed ID: 382359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hyperprolactinaemic patients with pergolide.
    L'Hermite M; Debusschere PM; Gillet C; Deschepper C
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):441-5. PubMed ID: 6412498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effects of suckling or transient dopamine antagonism on thyrotropin-releasing hormone and suckling induced prolactin release in lactating rats.
    Haisenleder DJ; Gala RR; Lawson DM
    Life Sci; 1986 Aug; 39(7):659-65. PubMed ID: 3090397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.